Tier A · Established human benefit
Tesamorelin
A real example of a peptide altering a specific fat compartment in humans.
Why researchers care
Potential human relevance
- Reduces excess abdominal fat in adults with HIV-associated lipodystrophy
- Raises endogenous GH and IGF-1 signaling through the physiologic axis
- Studied extensively in a clearly defined human population
What the human evidence says
Evidence, not extrapolation
Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Its approved indication is specific and should not be generalized into a universal fat-loss claim.
How to think about it
The Yooper Peptides take
Tesamorelin is valuable educationally because it shows the difference between “reducing visceral fat in a defined condition” and broad internet claims about effortless fat loss.
Primary / authoritative reading